A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Novartis
Mayo Clinic
Case Comprehensive Cancer Center
Incyte Corporation
Karyopharm Therapeutics Inc
Stanford University
BerGenBio ASA
Stanford University
OHSU Knight Cancer Institute
Sumitomo Pharma America, Inc.
Case Comprehensive Cancer Center
Incyte Corporation